Biotech RadarJobs updated

COMPANY

Trevi Therapeutics

HQ: New Haven, CT source · trevitherapeutics.com ↗ · New England

Clinical Phase 3

Keywords: respiratory idiopathic pulmonary fibrosis Prurigo Nodularis Uremic Pruritus Pruritus Refractory Chronic Cough Nodularis Prurigo Prurigo Hepatic Impairment Nalbuphine Opioid Abuse

Location: New Haven, CT · source · Oct 15, 2026

Profile checked Oct 10, 2026

$323.0MRaised (2 yrs)17Trials (company is sponsor)

Timeline

  1. Trial start Phase 3: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) Tablets source ↗
  2. Trial start Phase 3: Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) Tablets source ↗
  3. Trial start Phase 2: The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC) source ↗
  4. Raise Follow-on offering: $173M (total, as published), announced Apr 20, 2026. Source: company release on GlobeNewswire. source ↗
  5. Trial start Phase 1: A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy Participants source ↗
  6. Trial start Phase 1: NAL ER IPF Respiratory Function and Safety Study source ↗
  7. Trial start Phase 1: A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy Participants source ↗
  8. Raise Follow-on offering: $100M (total, as published), announced Jun 3, 2025. Source: SEC filing. source ↗
  9. Raise Follow-on offering: $50M (total, as published), announced Dec 16, 2024. Source: SEC filing. source ↗
  10. Trial start Phase 2: Cough Reduction in IPF With Nalbuphine ER source ↗
  11. Trial start Phase 2: Refractory Chronic Cough Improvement Via NAL ER (RIVER) source ↗
  12. Trial start Phase 2: A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of Cough source ↗
  13. Trial start Phase 1: Study of Nalbuphine ER in Participants With Hepatic Impairment source ↗
  14. Trial start Phase 2/Phase 3: PRISM Study-Pruritus Relief Through Itch Scratch Modulation source ↗
  15. Trial start Phase 1: Oral Abuse Potential Study of Nalbuphine source ↗
  16. Trial start Phase 2/Phase 3: Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis source ↗
  17. Trial start Phase 2/Phase 3: Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis source ↗
  18. Trial start Phase 2/Phase 3: Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic Pruritus source ↗
  19. Trial start Phase 2/Phase 3: Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus source ↗
  20. Trial start 1: Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus source ↗

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Funding

Raised: $323.0M. Last 2 years.

Clinical trials (lead sponsor) 17

RecordTitlePhaseStatusStartPrimary completion
NCT07868419Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine (NAL) Extended-Release (ER) TabletsPhase 3RecruitingSep 30, 20262027-08 (estimated)
NCT07671911Idiopathic Pulmonary Fibrosis (IPF)-Related Chronic Cough Reduction With Nalbuphine Extended-Release (NAL ER) TabletsPhase 3RecruitingJun 29, 20262028-06 (estimated)
NCT07487740A Food Effect Study to Evaluate the Relative Bioavailability of Nalbuphine Extended-Release Tablets (NAL ER) in Healthy ParticipantsPhase 1CompletedFeb 27, 2026May 11, 2026 (actual)
NCT07671924The Effect of Nalbuphine Extended-Release (NAL ER) on Cough in Participants With Refractory Chronic Cough (RCC)Phase 2RecruitingJun 22, 20262027-09 (estimated)
NCT07036029NAL ER IPF Respiratory Function and Safety StudyPhase 1CompletedAug 21, 2025Jun 30, 2026 (actual)
NCT05964335Cough Reduction in IPF With Nalbuphine ERPhase 2CompletedFeb 6, 2024Apr 24, 2025 (actual)
NCT05962151Refractory Chronic Cough Improvement Via NAL ER (RIVER)Phase 2CompletedNov 30, 2023Jan 6, 2025 (actual)
NCT04020016Study of Nalbuphine ER in Participants With Hepatic ImpairmentPhase 1CompletedJun 12, 2019Feb 5, 2020 (actual)
NCT07015398A Study of the Pharmacokinetic Interaction Between Pirfenidone, Nintedanib, and Nalbuphine Extended Release (NAL ER) in Healthy ParticipantsPhase 1CompletedJun 30, 2025Sep 12, 2025 (actual)
NCT03497975PRISM Study-Pruritus Relief Through Itch Scratch ModulationPhase 2/Phase 3CompletedAug 7, 2018May 10, 2022 (actual)
NCT04030026A Study of Nalbuphine (Extended Release) ER in Idiopathic Pulmonary Fibrosis (IPF) for Treatment of CoughPhase 2CompletedOct 29, 2019May 27, 2022 (actual)
NCT02373215Phase 1 Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic Pruritus1Completed2013-042013-11 (actual)
NCT02174419Study of Nalbuphine HCl ER Tablets in Patients With Prurigo NodularisPhase 2/Phase 3Completed2015-032016-08 (actual)
NCT02174432Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo NodularisPhase 2/Phase 3CompletedAug 15, 2015Sep 3, 2017 (actual)
NCT02143973Open Label Extension Study of Nalbuphine HCl ER in Hemodialysis Patients With Uremic PruritusPhase 2/Phase 3Completed2014-092016-01 (actual)
NCT04018664Oral Abuse Potential Study of NalbuphinePhase 1CompletedMay 29, 2018Dec 3, 2018 (actual)
NCT02143648Study of Nalbuphine HCl ER Tablets in Hemodialysis Patients With Uremic PruritusPhase 2/Phase 3Completed2014-062015-07 (actual)
Feedback